Livagen

What is Livagen?

Livagen is a chemically defined four-amino-acid peptide (H-Lys-Glu-Asp-Ala-OH, KEDA) from the short peptide-bioregulator research program associated with Khavinson and colleagues. Primary patent US7101854B2 describes synthesis, parenteral formulation, animal work, and one human clinical example.

Free-peptide formula C18H31N5O9, MW 461.48. Patent example finished product was associated with acetate; salt, moisture, and assay basis change gross mass vs free-peptide-equivalent mass.

Has Livagen been tested in humans?

[US7101854B2 Example 7](https://patents.google.com/patent/US7101854B2/en) is the only located source that clearly describes Livagen administration to living humans: 23 patients aged 32–53 with historical “chronic persistent hepatitis,” 0.01–100 µg/kg IM once daily for 10–40 days, vs 12 conventionally treated comparators.

The historical diagnosis requires caution — a modern replication needs cause-specific staging. Patent pre/post tables report symptom and lab changes in the active cohort (e.g., bilirubin, ALT, IgM marked significant in the source) but do not clearly report comparator outcomes or between-group analysis.

Human-cell / ex-vivo chromatin and enkephalinase studies are not dosing studies — they do not establish absorption, systemic dose, or clinical effect.

Livagen research dosage landscape

Patent and community amounts diverge because sellers start from 20 mg vial arithmetic, often substitute SC for patent IM without bridging data, and copy protocol language across sites. Nominal vial fill, salt mass, and free-peptide mass are frequently conflated.

Patent range by body weight (arithmetic only)

The following converts µg/kg tiers to daily mass. It is not personalization. The range spans four orders of magnitude — “use the middle” is not a scientifically valid dose-selection method.

Complete patent-anchored dose-verification protocol

Prospective Phase 1b-style framework for pure KEDA in adults with stable, compensated, cause-specific chronic liver disease. Preserves patent route, frequency, range, and minimum duration while adding PK, sentinel dosing, and stop rules the patent omitted.

Cohorts: 0.01, 0.1, 1, 10, 100 µg/kg IM once daily × 10 days. Escalation between cohorts only. Primary endpoints are safety/tolerability — not powered efficacy. IRB/ethics, hepatology, pharmacy, and independent safety review required before use.

The patent’s example 10 µg/mL solution fits Cohort 2 under this scheme but cannot deliver the top tier at a practical volume (700 mL for 7 mg). Higher concentrations need new validation. Do not double missed doses, escalate within a course, or start automatic repeat cycles.

Documented community titration (not a recommendation)

One circulating 12-week 20 mg-vial schedule escalates 0.5 → 1 → 1.5 → 2 mg SC daily, totaling ~126 mg nominal peptide over 84 days (≈6.3 × 20 mg vials before fill loss). Masses can fall numerically inside the patent µg/kg band for some body weights, but route, duration, titration, and identity remain unbridged.

Livagen reconstitution and vial math

Arithmetic assumes stated vial mass is assay-corrected KEDA — it does not establish identity, sterility, stability, or route suitability. U-100 markings are volume only.

Patent example 10 µg/mL is practical only at the low end of the µg/kg range; top-tier masses need higher validated concentrations.

A generic “28 days refrigerated” rule is not compound-specific stability evidence. HPLC area purity alone is not a quantitative content assay.

Preclinical research dosages

Patent and publications report hepatocyte culture at 5 ng/mL, explants highlighting 20 ng/mL, acute CCl4 models at 1 µg/rat IM, hepatoma work at 1 µg/kg SC × 10 days, and animal toxicology up to multi-mg/kg IM courses. These are model-specific and do not establish a human therapeutic window.

The hepatoma experiment is an animal-model observation — not evidence that Livagen treats cancer.

How might Livagen work?

Themes under investigation include hepatocyte protein synthesis, organotypic explant response, lymphocyte chromatin decondensation (ex vivo), and enkephalinase inhibition (IC50 20 µM ≈ 9.23 µg/mL in vitro — not a plasma target).

Human absorption, bioavailability, half-life, liver distribution, metabolites, dose-response, immunogenicity, and interactions remain unestablished.

Livagen safety

Patent animal toxicology reports no acute deaths up to 5 mg/kg IM in mice and no major pathology in multi-month rat studies — pre-modern reporting standards apply. The human patent example lacks a systematic AE dataset.

An experimental peptide should never delay cause-specific liver testing, antiviral care, alcohol-cessation support, DILI evaluation, or management of decompensated disease.

Route comparison

Can Livagen be stacked with other peptides?

No controlled human study establishes Livagen combinations with Epitalon, Vilon, Thymalin, BPC-157, TB-500, GHK-Cu, GH secretagogues, or other liver peptide complexes. The cleanest first study uses one verified KEDA product vs placebo with stable standard care.

Common claims vs evidence

Evidence ladder

Sport and regulatory context

Livagen is not named individually on the 2026 WADA list. S0 may still apply to non-approved pharmacologic substances. Tested athletes should obtain a ruling from their anti-doping organization before any exposure. No standardized US prescribing dose exists.

Bottom line

Livagen is KEDA (Lys-Glu-Asp-Ala) — not KED, KEDP, or a calf-liver extract. The strongest administered-human source is a patent describing 0.01–100 µg/kg IM once daily for 10–40 days without participant-level dose disclosure.

Cell, explant, and animal studies support biological activity in liver models but do not validate incompatible modern online milligram schedules. A rigorous next step is sequential, placebo-controlled, patent-anchored dose verification with identity testing, validated formulations, sentinel exposure, human PK, and modern cause-specific liver diagnostics.

Treat the patent’s 10,000-fold range as a range to investigate — not a dosing answer. Confirm KEDA identity before trusting any vial chart.

Frequently asked questions

References

• Khavinson VK

  US7101854B2 — Tetrapeptide stimulating hepatocyte functional activity

  Primary patent: identity, formulation, animal work, human example.

• PubChem

  Livagen CID 87919683

  Compound identity record.

• Brodskii VI et al.

  Protein-synthesis rhythm in rat hepatocytes and Livagen

  5 ng/mL culture exposure — preclinical.

• Khavinson VK et al.

  Livagen peptide and chromatin activation in lymphocytes from old people

  Ex-vivo mechanistic work — not systemic dosing.

• Kost NV et al.

  Livagen and Epitalon on enkephalin-degrading enzymes

  In-vitro IC50 20 µM — not a plasma target.

• Kuznik BI et al.

  Polypeptide liver complex and tetrapeptide KEDA review

  Distinguishes Ventvil extract from KEDA.

• WADA

  2026 Prohibited List

  Not named individually; S0 may apply.